Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

The EC approved Libtayo – a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells – based on data from the global open-label, multi-centre phase 3 EMPOWER ...

to produce optimized human antibodies and bispecific antibodies. Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others. On March 14, Evan Seigerman, an analyst from BMO ...

SAFEbody is a masking technology that aims to ensure that antibodies are only activated ... its Regeneron-partnered PD-1 checkpoint inhibitor Libtayo (cemiplimab), which still has modest sales ...

to produce optimized human antibodies and bispecific antibodies. Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others. On March 14, Evan Seigerman, an analyst from BMO ...

monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO® in patients with select solid tumorsFibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor ...

A new study suggests that targeting the protein alpha-synuclein could be a possible new target for treating melanoma.

Patients with a rare disease called mucous membrane pemphigoid are at risk of developing squamous cell carcinoma and basal cell carcinoma, finds a new study.